

Date: June 23, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Update in respect of our earlier intimations dated March 11, 2025, March 12, 2025 and April 22, 2025, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

With reference to our earlier intimations dated March 11, 2025, March 12, 2025, regarding acquisition of 8454 equity shares from certain shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix” or “the Target Company”), and further *vide* our intimation dated April 22, 2025 we informed that out of the said 8454 equity shares, the acquisition of 7914 equity shares have been completed and acquisition of 540 equity shares is under process due to requirement of certain approvals from Reserve Bank of India (“RBI”).

In respect of the same we would like further update that, since the said approvals from RBI are still awaited, hence in view of the same, the time-period for acquisition of the remaining 540 equity shares has been further extended by 60 (sixty) days from June 24, 2025.

The stakeholders are requested to take note of the same.

Thank you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263